Results 141 to 150 of about 125,716 (297)

Steatohepatitis: a tale of two "hits"?

Gastroenterology, 1998
C. Day, O. James
semanticscholar   +1 more source

Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine, 2021
V. Ratziu, L. D. de Guevara, R. Safadi, F. Poordad, F. Fuster, J. Flores-Figueroa, M. Arrese, A. Fracanzani, D. Ben Bashat, K. Lackner, T. Gorfine, S. Kadosh, R. Oren, M. Halperin, L. Hayardeny, R. Loomba, S. Friedman, M. F. M. J. P. E. F. C. F. Y. Z. T. M. J. E. M. D. S. Abdelmalek Angelico Angelico Arancibia Bardou-Jacq, M. Abdelmalek, F. Angelico, M. Angelico, J. P. Arancibia, E. Bardou-Jacquet, F. Barrera, C. Barish, Y. Baruch, Z. Ben‐Ari, T. Berg, M. Bourlière, J. Boursier, E. Broide, M. Carmiel, D. Denham, L. Di Cesare, D. Dumitrascu, A. Francis, S. Gawrieh, M. S. González Huezo, P. Hillon, A. Iracheta,, Z. Kayali, L. Kupčinskas, G. Lau, L. Serfaty, A. Le Cleach, C. Loguercio, M. Manns, B. I. Martinez Saldivar, E. Mena, L. A. Morales Garza, J. Neutel, L. Nikoleishvili, M. Noureddin, R. Pais, A. Paredes, M. Paredes, R. Peters Watkins, A. Picardi, M. Pirisi, G. Jofre, L. Preoțescu, T. Saadi, D. Samuel, J. F. Sánchez Avila, I. Schiefke, O. Shibolet, M. Siddiqui, G. Torres-Mendoza, J. Trotter, E. Tsai, E. Verna, E. Zuckerman, D. Zur, A. Sanyal   +73 more
semanticscholar   +1 more source

Natural History of Metabolic Dysfunction-Associated Steatotic Liver Disease: From Metabolic Syndrome to Hepatocellular Carcinoma

Medicina
Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) stems from disrupted lipid metabolism in the liver, often linked to obesity, type 2 diabetes, and dyslipidemia.
Melchor Alpízar Salazar, Samantha Estefanía Olguín Reyes, Andrea Medina Estévez, Julieta Alejandra Saturno Lobos, Jesús Manuel De Aldecoa Castillo, Juan Carlos Carrera Aguas, Samary Alaniz Monreal, José Antonio Navarro Rodríguez, Dulce María Fernanda Alpízar Sánchez   +8 more
doaj   +1 more source

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

New England Journal of Medicine, 2010
A. Sanyal, N. Chalasani, K. Kowdley, A. McCullough, A. Diehl, N. Bass, B. Neuschwander‐Tetri, J. Lavine, J. Tonascia, A. Unalp, M. V. Van Natta, J. Clark, E. Brunt, D. Kleiner, J. Hoofnagle, Patricia R. Robuck   +15 more
semanticscholar   +1 more source

Oral arginine supplementation protects female mice from the onset of non-alcoholic steatohepatitis [PDF]

, 2017
Cathrin Sellmann, Christian Degen, Cheng Jun Jin, Anika Nier, Anna Janina Engstler, Dana Alkhatib, Jean‐Pascal De Bandt, Ina Bergheim   +7 more
openalex   +1 more source

Pharmacological effects of gastrodin: Insight into neurological diseases and mechanism in ferroptosis and pyroptosis

Ibrain, Volume 11, Issue 1, Page 74-83, Spring 2025.
Pharmacological effects of gastrodin include prevention and treatment of cognitive decline and reperfusion injuries, anticonvulsion, antiepilepsy, antidepressants, and analgesia, which are related to antiferroptosis and antipyroptosis. Abstract Gastrodin, as an effective monomer of gastrodia elata, plays a significant role in anti‐inflammatory ...
Xue Zheng, Jing Li, Zhao‐Qiong Zhu
wiley   +1 more source

Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults

Alimentary Pharmacology and Therapeutics, 2011
G. Vernon, G. Vernon, A. Baranova, A. Baranova, Z. Younossi, Z. Younossi   +5 more
semanticscholar   +1 more source

PD‐1/PD‐L1 in Hepatocellular Carcinoma (2014–2024): A Combined Macro and Micro Analysis of Immunotherapy Implications

iNew Medicine, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) represents a significant global health issue, with the PD‐1/PD‐L1 axis serving a pivotal target for immunotherapy in this malignancy. However, a comprehensive bibliometric analysis of PD‐1/PD‐L1 research in HCC is lacking.
Xingyu Zhu, Lin Tang, Hongyan Li, Hao Li, Jiamei Wang   +4 more
wiley   +1 more source

Hydrogen-rich water prevents progression of nonalcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice [PDF]

, 2012
Daisuke Kawai, Akinobu Takaki, Atsuko Nakatsuka, Jun Wada, Naofumi Tamaki, Tetsuya Yasunaka, Kazuko Koike, Ryuichiro Tsuzaki, Kazuyuki Matsumoto, Yasuhiro Miyake, Hidenori Shiraha, Manabu Morita, Hirofumi Makino, Kazuhide Yamamoto   +13 more
openalex   +1 more source

Vibration‐controlled transient elastography in pediatric metabolic dysfunction‐associated steatotic liver disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a prevalent disease in children. Vibration‐controlled transient elastography (VCTE) offers a noninvasive alternative to liver biopsy, using controlled attenuation parameter (CAP) to estimate steatosis and liver stiffness measurement (LSM) for fibrosis.
Lauren B. Nichols, Sebastian G. J. Oakes, Cynthia Behling, Kathryn Harlow Adams, Mark H. Fishbein, Paula Hertel, Chao Jarasvaraparn, Jean P. Molleston, Marialena Mouzaki, Claude B. Sirlin, Miriam B. Vos, Laura A. Wilson, Stavra A. Xanthakos, Jeffrey B. Schwimmer, for the NASH CRN   +14 more
wiley   +1 more source